UK markets close in 3 hours 8 minutes

Pfizer Inc. (PFE)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
28.56+0.03 (+0.11%)
At close: 04:01PM EDT
28.52 -0.04 (-0.14%)
Pre-market: 08:22AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close28.53
Open28.47
Bid28.53 x 1800
Ask0.00 x 3000
Day's range28.32 - 28.67
52-week range25.20 - 40.37
Volume25,912,045
Avg. volume42,465,308
Market cap161.838B
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-0.05
Earnings date30 Jul 2024 - 05 Aug 2024
Forward dividend & yield1.68 (5.88%)
Ex-dividend date09 May 2024
1y target est31.48
  • Benzinga

    GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims

    GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid

  • Bloomberg

    GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay

    (Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML, TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Tesla Shareholder Group Slams Elon Musk’s

  • Benzinga

    Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute

    A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, infringed on Pfizer’s Wyeth unit’s patent rights. The jury found that AstraZeneca’s Tagrisso violated two patents held by Pfizer, which cover methods for treating cancer using the breast cancer drug Nerlynx. Also Read: Double Good News For AstraZeneca’s Breast Cancer Drugs. Puma Biotechnology Inc (